231
Views
4
CrossRef citations to date
0
Altmetric
Clinical Focus: Cardiometabolic Conditions - Review

A novel option for prandial insulin therapy: inhaled insulin

, , &
Pages 839-847 | Received 15 Apr 2016, Accepted 24 Aug 2016, Published online: 27 Sep 2016

References

  • IDF diabetes atlas. 6th ed. Brussels (Belgium): International Diabetes Federation; 2013.
  • Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
  • Nathan DM, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16.
  • Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia. Metabolism. 2006;55:1263–1281.
  • Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care. 2011;34:2237–2243.
  • Clark NG. Postprandial blood glucose, cardiovascular events, and all-cause mortality: how do we use postprandial glucose in clinical practice? Clin Diabetes. 2012;30:67–69.
  • Mata-Cases M, Mauricio D, Franch-Nadal J. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets. J Diabetes. 2016 Jan 8. doi:10.1111/1753-0407.12373. [Epub ahead of print].
  • Gordin D, Saraheimo M, Tuomikangas J, et al. Influence of postprandial hyperglycemic conditions on arterial stiffness in patients with type 2 diabetes. J Clin Endocrinol Metab. 2016;101:1134–1143.
  • Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab. 2013;15(Suppl 2):3–8.
  • Sartore G, Chilelli NC, Burlina S, et al. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol. 2013;50:437–442.
  • Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 Executive Summary. Endocr Pract. 2016;22:84–113.
  • Inzucchi SE, Bergenstal RM, Buse JM, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
  • Schrot RJ. Targeting plasma glucose: preprandial versus postprandial. Clin Diabetes. 2004;22:169–172.
  • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
  • Subramanian S, Hirsch IB. Personalized diabetes management: moving from algorithmic to individualized therapy. Diabetes Spectr. 2014;27:87–91.
  • Riddle MC. The transition from oral agents to combination insulin/oral therapy. In: Feinglos MN, Bethel MA, editors. Contemporary endocrinology: Type 2 diabetes mellitus: an evidence-based approach to practical management. Totowa (NJ): Humana Press; 2008. p. 169–181.
  • Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes. The scope of the problem. Diabetes Care. 2005;28:2543–2545.
  • Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2005;28:2673–2679.
  • Kugler AJ, Fabbio KL, Pham DQ, et al. Inhaled technosphere insulin: a novel delivery system and formulation for the treatment of types 1 and 2 diabetes mellitus. Pharmacotherapy. 2015;35:298–314.
  • Heise T, Meneghini LF. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract. 2014;20:75–83.
  • US FDA. Press Announcements: FDA approves Afrezza to treat diabetes; [cited 2014 Jun 27; updated 2015 Dec 17]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122
  • Kokić S, Buković D, Radman M, et al. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. Coll Antropol. 2003;27:181–187.
  • Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2005;143:549–558.
  • Pala L, Mannucci E, Dicembrini I, et al. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Res Clin Pract. 2007;78:132–135.
  • Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–1730.
  • Yamashiro K, Ikeda F, Fujitani Y, et al. Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes. J Diabetes Investig. 2010;1:149–153.
  • Brunton SA. Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus. Postgrad Med. 2012;124:74–83.
  • Hamnvik OP, McMahon GT. Balancing risk and benefit with oral hypoglycemic drugs. Mt Sinai J Med. 2009;76:234–243.
  • Du YF, Ou HY, Beverly EA, et al. Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. Clin Interv Aging. 2014;9:1963–1980.
  • Phillips P. Type 2 diabetes - failure, blame and guilt in the adoption of insulin therapy. Rev Diabet Stud. 2005;2:35–39.
  • Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care. 2010;33:240–245.
  • Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29:682–689.
  • Davies MJ, Gagliardino JJ, Gray LJ, et al. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30:512–524.
  • Donnelly LA, Morris AD, Evans JM, et al. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100:345–350.
  • García-Pérez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175–194.
  • Sarala N, Bengalorkar G, Bhuvana K. Technosphere: new drug delivery system for inhaled insulin. Fut Prescriber. 2012;13:14–16.
  • Cassidy JP, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere Insulin inhalation powder administration. Pharm Res. 2011;28:2157–2164.
  • Ledet G, Graves RA, Bostanian LA, et al. A second-generation inhaled insulin for diabetes mellitus. Am J Health Syst Pharm. 2015;72:1181–1187.
  • Marino MK, Cassidy JP, Smutney CC, et al. Bioequivalence and dose proportionality of AFREZZA® inhalation powder administered using a Gen2 inhaler compared to the Medtone® inhaler. Presented at the Diabetes Technology Meeting; 2010 Nov 11–13; Bethesda (MD). Poster #142. Available from: http://www.mannkindcorp.com/collateral/documents/english-us/2010-dts-poster-142-be-final-lr-11.10.10.pdf.
  • Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014;127(10 Suppl):S25–38.
  • Rave K, Potocka E, Heinemann L, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11:715–720.
  • Rave K, Heise T, Heinemann L, et al. Inhaled Technosphere insulin in comparison to subcutaneous regular insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008;2:205–212.
  • Humalog Prescribing Information. 2015 [cited 2015 Dec 17]. Available from: http://pi.lilly.com/us/humalog-pen-pi.pdf
  • Apidra Prescribing Information. 2009 [cited 2015 Dec 17]. Available from: http://medconnections.com/drugs/pdf/apidra.pdf
  • Novalog Prescribing Information. 2010 [cited 2015 Dec 17]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM214655.pdf
  • Afrezza Prescribing Information. 2014 [cited 2015 Dec 17]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022472lbl.pdf
  • Rosenstock J, Bergenstal R, Defronzo RA, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008;31:2177–2182.
  • Rendell M. Technosphere inhaled insulin (Afrezza). Drugs Today (Barc). 2014;50:813–827.
  • Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab. 2012;14:163–173.
  • US FDA. Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting, April 1, 2014 [cited 2015 Dec 17]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390864.pdf
  • Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38:2266–2273.
  • Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375:2244–2253.
  • Rosenstock J, Franco D, Korpachev V, et al. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care. 2015;38:2274–2281.
  • Pittas AG, Westcott GP, Balk EM. Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3:886–894.
  • Muchmore DB, Vaughn DE. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase. J Diabetes Sci Technol. 2012;6:764–772.
  • Zisser H, Jovanovic L, Markova K, et al. Technosphere insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2012;14:997–1001.
  • Peyrot M, Rubin RR. Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther. 2010;12:49–55.
  • Tack CJ, Christov V, de Galan BE, et al. Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol. 2008;2:47–57.
  • Sanofi-Aventis US. Dosing Guide for Afrezza®. 2015 [cited 2016 Jan 6]. Available from: http://hcp.afrezza.com/AfrezzaConfigurationChart.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.